Ridge Pharma

NVM Private Equity (NVM) has invested £2.75 million of growth capital (with the balance of the £3.2m funding round provided by existing investors and private individuals) into Reading-based pharmaceutical company Ridge Pharma Limited (“Ridge”). Ridge is an emerging UK pharmaceutical business set to commercialise their first product in late 2018, with further launches thereafter. Ridge was founded on the belief that consistently offering medicines with distinct benefits and clear value is at the heart of a rewarding and sustainable business.

Founded in 2017 by Chief Executive Officer, Brendon McDonagh, and Harry Stratford, Ridge Pharma is focused on the in-licensing and marketing of prescription medicines. Brendon has over 20 years of commercial experience in the pharmaceutical industry, beginning his career at ProStrakan and most recently as Country Manager for Consilient Health, leading the success of their UK branded business. Brendon is passionate about challenging established prescription markets for the benefit of the NHS and patients.

Harry Stratford OBE is the Non-Executive Chairman of Ridge Pharma. He brings a wealth of experience from over 40 years in the pharmaceutical industry, notably as founder and CEO of Shire Pharmaceuticals Plc, and as founder, CEO and Executive Chairman of ProStrakan, subsequently acquired by Kyowa Hakko Kirin in 2011. He now holds a number of non-executive board positions, and is currently Non-Executive Chairman of Amryt Pharma.

“We are delighted to have NVM Private Equity as our partner in building a leading UK pharmaceutical company. From the outset they have shared and supported our ambition to build a sustainable business, with strong ethical principles, that delivers exceptional value to all our stakeholders, from patients to our employees.”

Brendan McDonagh, Founder and CEO of the company